

Published in final edited form as:

*Future Med Chem.* 2012 September ; 4(13): 1751–1761. doi:10.4155/fmc.12.124.

## Natural products as a rich source of tau-targeting drugs for Alzheimer's disease

Laurent Calcul<sup>1</sup>, Bo Zhang<sup>2</sup>, Umesh K Jinwal<sup>3</sup>, Chad A Dickey<sup>2</sup>, and Bill J Baker<sup>1,\*</sup>

<sup>1</sup>Department of Chemistry & Center for Drug Discovery & Innovation, University of South Florida, FL, USA

<sup>2</sup>Department of Molecular Medicine & USF Health Byrd Alzheimer's Institute, University of South Florida, FL, USA

<sup>3</sup>Department of Pharmaceutical Sciences & USF Health Byrd Alzheimer's Institute, University of South Florida, FL, USA

### Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder and the most common form of dementia, affecting more than 5.4 million people in the USA. Although the cause of AD is not well understood, the cholinergic, amyloid and tau hypotheses were proposed to explain its development. Drug discovery for AD based on the cholinergic and amyloid theories have not been effective. In this article we summarize tau-based natural products as AD therapeutics from a variety of biological sources, including the anti-amyloid agent curcumin, isolated from turmeric, the microtubule stabilizer paclitaxel, from the Pacific Yew *Taxus brevifolia*, and the Streptomyces-derived Hsp90 inhibitor, geldanamycin. The overlooked approach of clearing tau aggregation will most likely be the next objective for AD drug discovery.

---

**Alzheimer's disease** (AD) was first described in 1906 by Aloisius 'Alois' Alzheimer, a German psychiatrist and neuropathologist who identified and described amyloid plaques (A $\beta$ ) and neurofibrillary tangles (NFTs) from a 51-year old patient named Auguste Deter who showed strangely impaired behavior [1]. The observed symptoms for AD are related to cognitive decline, memory loss, confusion, problems with reading, writing and speaking, along with changes in mood and personality. As the disease progresses, AD patients withdraw more and more from work and social activities to depend on total care from caregivers [2]. Since Alois Alzheimer described the disease, its cause remains unknown except for less than 5% of the cases that are genetic, with mutations observed in amyloid precursor protein [3], presenilin-1 and -2 [4], displaying autosomal-dominant familial AD, and in the autosomal-recessive AD apolipoprotein E-e4 (*ApoE4*) [5]. Several hypotheses have been proposed to explain the onset and development of AD. The cholinergic hypothesis states that low production of acetylcholine (ACh) initiates AD, while the observation of A $\beta$  and NFTs lead to the amyloid and **tau** hypotheses as causes for AD development.

---

© 2012 Future Science Ltd

\*Author for correspondence: bjbaker@usf.edu.

#### Financial & competing interests disclosure

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

## The acetylcholine strategy

The cholinergic hypothesis of AD arose after deficits in the neurotransmitter ACh were noted in AD patients. ACh activity is regulated by the serine protease AChE, which breaks down ACh in the CNS by catalyzing the hydrolysis of ACh to acetate and choline (Figure 1) [6]. Therapy is based on drugs inhibiting AChE, which inactivates ACh at the synapse. The inhibition of AChE prevents the normal breakdown of ACh to compensate for the low concentrations of ACh that are characteristic of AD.

## From the amyloid hypothesis to tau

The hallmarks of AD are largely twofold: insoluble deposits of A $\beta$  located between neurons and clumps of NFTs composed of tau aggregates found within nerve cells. Initially, the A $\beta$  theory prevailed against the tau theory, especially as mutations were identified in the amyloid precursor protein located on chromosome 21 that corresponds to amyloid build-up and AD phenotypes. More recently, however, the tau hypothesis has gained traction. The tau protein stabilizes microtubules in neurons, but abnormal hyperphosphorylation of tau leads to aggregate formation. Diseases known to present with these aggregates are termed tauopathies, of which the most well-known is AD [7–12]. Although these insoluble visible tangles correlate strongly with AD severity post-mortem [13], they may merely be the cell's response to the advent of AD pathology. Soluble tau intermediates are more neurotoxic than higher order aggregates and are responsible for the cognitive dysfunction in AD and other tauopathies (Figure 2) [14–17]. Mutations in the coding and noncoding portions of the tau gene have also been directly associated with the development of the condition referred to as frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17) [18,19]. Thus, despite a few efforts aimed at preventing tau aggregation [15,20], a more beneficial approach towards AD therapeutics may be to enhance tau clearance [21]. Targeting the microtubule-associated protein tau (MAPT) that pathologically accumulates in AD and the paired helical filaments (PHFs) that are indicative of AD NFTs may perhaps be the most effective strategy for treating post-symptomatic AD [14–16,22–26]. Furthermore, the recent failures of A $\beta$ -targeted therapeutics in Phase III clinical trials suggest that it is both timely and prudent to consider alternative drug-discovery strategies for AD.

## Pharmaceutical AD treatments

Currently, there are no cures for AD, and only five available drugs for treating symptoms: four AChE inhibitors, drugs developed based solely on the cholinergic hypothesis and one *N*-methyl-D-aspartate (i.e., NMDA)-receptor antagonist (Table 1) [27,201]. The first AD drugs, starting with Cognex<sup>®</sup> (tacrine) in 1993, were developed based on the cholinergic hypothesis of AD. Cognex<sup>®</sup>, Aricept<sup>®</sup> (donepezil), Exelon<sup>®</sup> (rivastigmine) and Razadyne<sup>®</sup> (**galantamine**) are all AChE inhibitors, and the hope was that inhibiting AChE activity would maintain ACh levels in AD patients (Table I). The more recently approved drug memantine differs slightly in its approach by acting on the glutamatergic system instead, but its efficacy seems restricted to those with moderate to severe AD, and it displays limited effects [28,29].

Among the available drugs, one is a natural product. Galantamine (**1**; Figure 3) is an **alkaloid** isolated from the bulbous herbaceous plant *Galanthus woronowii* (Caucasian snow-drop) and bulbs of different species in the Amaryllidaceae family (*Amaryllis*, *Hippeastrum*, *Lycoris*, *Ungernia*, *Leucojum*, *Narcissus*, *Zephyranthes*, *Hymenocallis* and *Haemanthus* genera)[30]. It is important to note that rivastigmine (**2**) is a synthetic analog of the cholinesterase inhibitor alkaloid physostigmine (**3**) from the poisonous seeds of *Physostigma venosum* (calabar bean) [31]. The cholinergic-based drugs are considered to only ease the

symptoms of AD and not to prevent the progression of the disease; however, AChE inhibitors may have disease-modifying effects [32].

Recent focus on future AD therapeutics has been on reducing A $\beta$  levels, and NFTs production resulting from the hyperphosphorylation of the tau protein has received little attention, despite clinical trials suggesting that tau-based therapies may be more relevant than anti-A $\beta$  compounds in patients already presenting with AD symptoms [33]. Therefore, there is a significant need for efficient drugs against AD with tau-reducing properties. These drugs can be synthesized or harvested from nature, the advantage of the latter being the potential for chemical diversity, biological selectivity and favorable properties. The majority of current drugs on the market are natural product-derived compounds [34].

## Current approaches to reduce the effects of tau dysfunction in AD

A number of strategies have been used to search for the best way to decrease tau levels in neurons. They vary from inhibiting formation of tau aggregates, regulating tau using kinases, controlling tau degradation via chaperones and stabilizing tau microtubules. Current biochemical assays focus on inhibiting tau fibrillization [15,35]. While this approach may yield novel compounds, recent work suggests tau aggregation may actually be a protective mechanism employed by neurons and the most toxic entities are tau intermediates [15,36,37]. A number of proline-directed kinases (ERK2, GSK-3 and CDK5), nonproline-directed enzymes (CK1 and PKA) and microtubule affinity-regulating kinases (MARKs) are known to be involved in the process of tau phosphorylation [38–40]. Manipulations of kinases by drugs have been shown to be an effective way to reduce tau levels; for example, a small-molecule inhibitor of GSK-3 $\beta$  kinase was effective in reducing phosphorylated tau [41,42]. Alternatively, affecting molecular chaperone protein functions may have deleterious effects on tau as well, since inhibiting the molecular chaperone Hsp90 showed positive effects in reducing phosphorylated and misfolded tau [21]. Hyperphosphorylated tau is also known to destabilize microtubules and cause impairment in microtubule function and axonal transport, leading to the idea that microtubule-stabilizing agents may help compensate for these losses [43,44].

## Natural products as tau targeting agents

Several natural products already evaluated for their efficacy in treating AD have been previously summarized in literature [45,46]. Since recent clinical trials suggested tau-based therapies may be more effective than anti-A $\beta$  treatments for patients already presenting AD symptoms, the relative paucity of tau-reducing agents needs to be addressed. Examples of anti-tau diets (diets aiding in reducing tau) indicate the potential of utilizing natural products as future treatments for AD. Summarized below are natural products reported to date, from terrestrial and marine plants, invertebrates and algae, as well as microorganisms, which have been found active in tau-related screens.

Scientists have looked to dietary sources, including extracts and preparations of ethnobotanical plants, for relief of neurodegenerative disorders [47,48]; recent efforts to uncover the chemical basis of these materials have identified a number of bioactive metabolites, some with drug-development potential. Many anti-tau natural products made by plants are **polyphenols** such as **curcumin (4)**; Figure 4), a linear diarylheptanoid present at 66.8% of an optimized turmeric (*Curcuma longa*) extract [49]. This extract, in addition to acting as an antioxidant, was observed to significantly increase production of the anti-inflammatory cytokine IL-4 and to reduce A $\beta$  and tau levels in A $\beta$ -overexpressing mice [50]. Furthermore, our group has identified a potent macrocyclic diarylheptanoid from bayberry root bark (*Myrica cerifera*) extract, (+)-*aR*,11*S*-myricanol (**5**) that reduces tau

levels [51]. Compound **5** reduced tau levels *ex vivo* in a cell culture model of tauopathy (in HeLa-C3 cells) with an EC<sub>50</sub> value of 35 μM and is a suitable scaffold for AD drug discovery [101]. The isolation of (+)-*aR*,11*S*-myricanol (**5**) was accompanied by additional bayberry flavonoids, including myricetin (**6**) and its rhamnoside glycoside myricitrin (**7**). Low micromolar tau filament formation inhibition of myricetin was previously reported *in vitro* as well as for two other members of the flavonoid family the roselle (*Hibiscus sabdariffa*)-derived gossypetin (**8**) [52] and the green tea (*Camellia sinensis*)-derived (–)-epicatechin-3-gallate (**9**) [53] showing IC<sub>50</sub> values at 1.2, 2.0 and 1.8 μM, respectively [54]. A cinnamon (*Cinnamomum zeylanicum*) extract inhibiting aggregation of human tau *in vitro* leads to an inhibitory activity attributable to both compounds cinnamaldehyde (**10**) and A-type doubly linked procyanidin oligomers of the catechins/epicatechin structural classes (**11**) [55]. Similar procyanidins identified from grape seed (*Vitis vinifera*)-derived polyphenolic extracts were found to prevent tau fibrillization into neurotoxic aggregates [56]. Investigation of sage (*Salvia officinalis*) as a culinary source for improving cognition and memory showed that the active ingredient was the polyphenol rosmarinic acid (**12**), which reduced tau hyperphosphorylation in addition to attenuating several AD pathways, such as reactive oxygen species formation, lipid peroxidation, DNA fragmentation, caspase-3 activation and Aβ accumulation [57].

Other plant and dietary sources with tau-modifying effects produce compounds that are not polyphenols. Tanshinone IIA (**13**; Figure 5), a norditerpene from red sage (*Salvia miltiorrhiza*), possesses protective effects against neurotoxicity and tau hyperphosphorylation induced by β-amyloid at 10 μM [58], whereas the lignans **14** and **15**, and the isoflavane **16**, from the water soluble extract of Chinese Yew, *Taxus yunnanensis*, revealed stimulatory effects on GSK-3β at 10 μM, preferentially phosphorylating serine residues rather than threonine residues on recombinant human tau protein (rhTP) [59]. The known microtubule stabilizer drug (MSD) paclitaxel (**25**; Figure 6) from the Pacific Yew, *Taxus brevifolia*, showed positive results in neurodegenerative tauopathy by counteracting ‘loss-of-function’ effects of tau pathology in a transgenic mouse model [44]. Oleocanthal (**17**), from olive oil (*Olea europaea*), was tested for inhibition of filament formation of the longest tau isoform T40 and the corresponding microtubule-binding region K18, displaying IC<sub>50</sub> values of 20 and 2.9 μM, respectively [60]. The anthroquinone emodin (**18**), isolated from the root and rhizome of rhubarb, *Rheum palmatum*, displays inhibition of PHFs [61]. Levels of tau-1 were found to decrease in ovariectomized rats (which hold similar pathology to menopausal women with AD) after 4 weeks of drinking the juice of young coconut (*Cocos nucifera*). Young coconut juice contains estrogen-like substances such as estrone (**19**), 17-β-estradiol (**20**) and β-sitosterol (**21**), which are implicated in the observed effects on tau [62]. The steroid glycoside ginsenoside Rd (**22**) from Asian ginseng, *Panax ginseng*, shows *in vivo* and *in vitro* reduction of neurotoxicity and tau hyperphosphorylation by enhancing the activities of PP-2A [63]. Aged garlic (*Allium sativum*) extract has sulfur-containing constituents *S*-allyl-cysteine (**23**) (water-soluble component of garlic) and diallyl-disulfide (**24**) (lipid-soluble component of garlic), which exhibited anti-amyloidogenic, anti-inflammatory and anti-tangle effects [64].

Tau-reducing compounds are not limited to plant sources; however, in addition to those listed above, bacterial- and fungal-derived compounds with anti-tau activity have been reported. Most are **quinone** derivatives such as the anthraquinones, daunorubicin (**26**; Figure 7) and adriamycin (**27**) isolated from the bacterium *Streptomyces peucetius*, along with the previously discussed compound emodin (**18**). Both compounds **26** and **27** displayed tau aggregation inhibition activity, dissolving PHFs *in vitro* and in cells [61]. From the fungal kingdom, the anthraquinone rubellins were isolated from the phytopathogenic fungus *Ramularia collo-cygni* [65]. After broad bioactivity profiling, rubellins B, D and E (**28–30**)

were found to inhibit the formation of tau aggregates with IC<sub>50</sub> values of 1.2, 0.9 and 0.9 μM, respectively, and to promote the disassembly of tau aggregates with DC<sub>50</sub>'s of 1.6, 2.2 and 0.5 μM, respectively. Benzoquinone macrocyclic polyketide geldanamycin (**31**), isolated from the related microbe *Streptomyces hygroscopicus* [66], was identified as an inhibitor of Hsp90 and reported to reduce levels of hyperphosphorylated tau [21]. While tetracycline (**32**), a compound isolated from *Streptomyces* spp., inhibited and disassembled Aβ fibrils [67], its synthetic derivative **minocycline** (**33**) showed additional capacities such as neuroprotection [68], microglial activation [69], caspase-3 activation inhibition, and reduction of tau hyperphosphorylation [70]. Minocycline is currently being tested in a Phase II clinical trial in AD (Table 1).

Transgenic mice with existing tau pathology treated with the myxobacteria (*Sorangium cellulosum*)-derived MSD macrocyclic polyketide epothilone D (**34**; Figure 8) had less forebrain tau pathology, with a reduction of axonal dystrophy and an increase of axonal microtubule density [71]. Tau tangles are still present in the optic nerve, which is expected. Improving MT function and axonal integrity with a MSD may not alter tau phosphorylation and aggregation, but may compensate for the loss-of-function of tau [44].

Microbial action on plant litter polyphenolics produces complex mixtures of higher order polyphenolics known as fulvic and humic acids. Fulvic acid standard I (**35**) (Suwannee River I 1S101F), was found to inhibit aggregation of tau fibrils *in vitro* with an IC<sub>50</sub> value of 37 μM and promote the disassembly of tau fibrils with a DC<sub>50</sub> value of 95 μM [72]. Fulvic acid also represents a major component of the Indian Ayurvedic traditional medicine *shilajit*, a tar-like substance reported to control aging-related cognitive disorders [73].

Further tau-reducing compounds are found in marine organisms such as sponges and sea snails. Peloruside A (**36**; Figure 9) is a MSD isolated from the marine sponge *Mycale hentscheli* with the same mode of action as paclitaxel [74]. Palinurin (**37**), a linear furanosesterterpene from sponges of the genus *Ircinia* (*I. variabilis*, *I. dendroides* and *I. oros*), emerged as a non-ATP competitive inhibitor of GSK-3β with an IC<sub>50</sub> value of 4.5 μM [75,102], resulting in reduction of tau hyperphosphorylation. Marine alkaloids have also been evaluated against GSK-3β. Manzamine A (**38**), isolated from the sponge *Haliclona* sp. [76], and hymenaldisine (**39**), first isolated from two sponges *Axinella verrucosa* and *Acanthella aurantiaca* [77], inhibited cyclin-dependent kinases, displaying IC<sub>50</sub> values toward GSK-3β of 10 μM [78] and 35 nM, respectively [79]. Finally, the *bis*-indole alkaloids indirubins are constituents of a dye extracted from gasteropod mollusks of the Muricidae and Thaididae families. 6-bromoindirubin (**40**) from the Mediterranean mollusk *Hexaplex trunculus* and its synthetic derivative 6-bromoindirubins-3'-oxime (**41**) display an impressive selectivity toward, and inhibition of, GSK-3β with IC<sub>50</sub> values of 45 and 5 nM, respectively [80]. These outstanding results show that brominated *bis*-indoles may prove to be good candidates to develop for their ability to reduce tau.

## Development of natural products as tau-modifying compounds in AD

Little is currently known about structure–activity or structure–property relationships of these natural products. In the case of flavonoid polyphenols, it appears *ortho*-substituted phenol groups are required for tau reduction, based on comparison of (–)-epicatechin-3-gallate (**9**) to (–)-epicatechin, the latter of which is not active [54]. The same observation is noted with polyphenols for α-synuclein and prion protein aggregation [81,82]. A protein/small-molecule interaction mechanism study revealed that the tau fibrillogenic fragment K18 is likely to be covalently modified by oleocanthal through Schiff base formation between the ε-amino group of the lysine residues and oleocanthalaldehyde carbonyls, which inhibits tau fibrillation [83]. However, further studies are needed to clarify the interaction between tau-

reducing small molecules and the protein. In addition, the exact mechanism of tau oligomer formation remains to be elucidated. Furthermore the blood–brain barrier (BBB), the semi-permeable protective shield surrounding the brain to restrict substances in the blood from entering the CNS, can present developmental challenges for drugs in AD. Crossing the BBB requires a drug with low molecular weight and lipid solubility [84]. Few permeability studies have been conducted on the natural products discussed above. However, curcumin (**4**) was found effective at crossing the BBB [85]. Other tau-reducing polyphenols of the proanthocyanidin and flavonoid classes may be good candidates for AD leads as a result of having similar chemical character to curcumin [86,87]. On the other hand, the anticancer MSD paclitaxel (**25**) and related taxanes showed poor BBB permeability, suggesting smaller or more lipophilic natural products may be more successful [88]. Indeed, epothilone D (**34**), another MSD, is a brain penetrant and safe at low doses [71]. The indirubins displayed *in vivo* efficacy, highlighting their facility in crossing the BBB and suggesting these compounds may warrant development as therapeutic agents in AD and other neurodegenerative disorders [79].

## Future perspective

Overall, we have focused this review on tau-based therapeutics for AD. We have summarized current literature describing anti-tau compounds from nature as potential agents to treat AD. Natural products from different biological sources, such as plants, fungi, bacteria, marine sponges and mollusks have been evaluated for their tau protein modulation. Discovery and development of compounds along this line will require stronger knowledge of the mode of action of the disease. Furthermore, any newly discovered drug leads must have favorable BBB permeability and suitable pharmacodynamic properties.

## Acknowledgments

The authors of this review were supported by Grants from NIH/NINDS (R01NS073899), the Alzheimer's Association, Alzheimer's Drug Discovery Foundation and CurePSP.

## Key Terms

<b>Alzheimer's disease</b>	Most common form of neurodegenerative disorder affecting memory, thinking and behavior. It is characterized by the gradual loss of neurons and synapses in the brain and leads to death.
<b>Tau</b>	Microtubule-stabilizing protein abundant in neurons of the CNS. The abnormal function of tau leads to neurodegenerative disorders such as Alzheimer's disease.
<b>Galantamine</b>	AChE inhibitor that is the first and, currently, only natural product used as a drug to treat symptoms of Alzheimer's disease.
<b>Alkaloid</b>	Organic substance containing basic nitrogen atoms.
<b>Polyphenol</b>	Organic substance characterized by the presence of multiple phenol structural units.
<b>Curcumin</b>	Principal constituent of the indian spice turmeric ( <i>Curcuma longa</i> ). A broad range of therapeutic properties toward cancer, autoimmune diseases and Alzheimer's disease are attributed to curcumin.
<b>Paclitaxel</b>	Yew tree-derived antimetabolic drug used in cancer chemotherapy that has been studied as a treatment for Alzheimer's disease.
<b>Quinone</b>	Aromatic organic substance characterized by fully conjugated dienes.

<b>Minocycline</b>	Tetracycline antibiotic primarily used in treating acne. Minocycline shows a broad spectrum of activities, including Alzheimer's disease-treatment properties.
--------------------	--

## References

Papers of special note have been highlighted as:

- of interest
- ■ of considerable interest

1. Prince, M.; Bryce, R.; Ferri, C. World Alzheimer Report. London, UK: Alzheimer's Disease International; 2011. p. 1-36.
2. Freeman WJ. Alzheimer: the life of a physician and the career of a disease. *J. Am. Med. Assoc.* 2005; 293:745–746.
3. Lott IT, Head E. Alzheimer disease and down syndrome: factors in pathogenesis. *Neurobiol. Aging.* 2005; 26:383–389. [PubMed: 15639317]
4. Waring SC, Rosenberg RN. Genome-wide association studies in Alzheimer disease. *Arch. Neurol.* 2008; 65:329–334. [PubMed: 18332245]
5. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology including Alzheimer's disease. *Proc. Natl Acad. Sci. USA.* 2006; 103:5644–5651. [PubMed: 16567625]
6. Bartus RT, Dean RL, Pontecorvo MJ, Flicker C. The cholinergic hypothesis: a historical overview, current perspective, and future directions. *Ann. NY Acad. Sci.* 1985; 444:332–358. [PubMed: 2990293]
7. Garcia ML, Cleveland DW. Going new places using an old MAP: tau, microtubules and human neurodegenerative disease. *Curr. Opin. Cell Biol.* 2001; 13:41–48. [PubMed: 11163132]
8. Cassimeris L, Spittle C. Regulation of microtubule associated protein. *Int. Rev. Cytol.* 2001; 210:163–226. [PubMed: 11580206]
9. Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, Ghetti B. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. *Proc. Natl Acad. Sci. USA.* 1998; 95:7737–7741. [PubMed: 9636220]
10. Hutton M, Lendon CL, Rizzu P, et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. *Nature.* 1998; 393:702–705. [PubMed: 9641683]
11. Hardy J, Orr H. The genetics of neurodegenerative diseases. *J. Neurochem.* 2006; 97:1690–1699. [PubMed: 16805777]
12. Goedert M, Spillantini MG, Crowther RA, et al. Tau gene mutation in familial progressive subcortical gliosis. *Nat. Med.* 1999; 5:454–457. [PubMed: 10202939]
13. Van Marum RJ. Current and future therapy in Alzheimer's disease. *Fundam. Clin. Pharmacol.* 2008; 22:265–274. [PubMed: 18485144]
14. Santacruz K, Lewis J, Spire T, et al. Tau suppression in a neurodegenerative mouse model improves memory function. *Science.* 2005; 309:476–448. [PubMed: 16020737]
15. Spire-Jones TL, de Calignon A, Matsui T, et al. *In vivo* imaging reveals dissociation between caspase activation and acute neuronal death in tangle-bearing neurons. *Neuroscience.* 2008; 28:862–867. [PubMed: 18216194]
16. Congdon EE, Necula M, Blackstone RD, Kuret J. Potency of a tau fibrillization inhibitor is influenced by its aggregation state. *Arch. Biochem. Biophys.* 2007; 465:127–135. [PubMed: 17559794]
17. Oddo S, Vasilevko V, Caccamo A, Kitazawa M, Cribbs DH, La Ferla FM. Reduction of soluble A $\beta$  and tau, but not Soluble A $\beta$  alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. *J. Biol. Chem.* 2006; 281:39413–39423. [PubMed: 17056594]
18. Goedert M. Tau gene mutations and their effects. *Mov. Disord.* 2005; 20:45–52.

19. Goedert M, Jakes R. Mutations causing neurodegenerative tauopathies. *Biochim. Biophys. Acta Mol. Basis Dis.* 2005; 1739:240–250. ■ The clear influence of the tau protein in neurodegenerative diseases, such as Alzheimer's disease and the inherited frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).
20. Wischik CM, Edwards PC, Lai RY, Roth M, Harrington CR. Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. *Proc. Natl Acad. Sci. USA.* 1996; 93:11213–11218. [PubMed: 8855335]
21. Dickey CA, Kamal A, Lundgren K, et al. The high-affinity HSP90–CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. *J. Clin. Invest.* 2007; 117:648–658. [PubMed: 17304350]
22. Green RC, Schneider LS, Amato DA, et al. Effect of Tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease. *J. Am. Med. Assoc.* 2009; 302:2557–2564.
23. Gauthier S, Aisen PS, Ferris SH, et al. Effect of Tramiprosate in Patients with Mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study. *J. Nutr. Health Aging.* 2009; 13:550–557. [PubMed: 19536424]
24. Lyketsos CG, Breitner JC, Green RC, et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. *Neurology.* 2007; 68:1800–1808. [PubMed: 17460158]
25. Crystal H, Dickson D, Fuld P, et al. Clinicopathological studies in dementia: nondemented subjects with pathological confirmed Alzheimer's disease. *Neurology.* 1988; 38:1682–1687. [PubMed: 3185902]
26. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol. (Ber.).* 1991; 82:239–259.
27. Kramp VP. List of drugs in development for neurodegenerative diseases: update October 2011. *Neurodegen. Dis.* 2012; 9:210–283.
28. Mount C, Downton C. Alzheimer disease: progress or profit? *Nat. Med.* 2006; 12:780–784. [PubMed: 16829947]
29. Areosa SA, Sherriff F, McShane R. Memantine for dementia. *Coch. Data. Syst. Rev.* 2006; 2:1–77.
30. Brekov S, Georgieva L, Kondakova V, et al. Plant sources of Galathamine: phytochemical and biotechnological aspects. *Biotechnol. Biotechnol. Eq.* 2009; 23:1170–1176.
31. Nordberg A, Svensson AL. Cholinesterase inhibitors in the treatment of Alzheimer disease: a comparison of tolerability and pharmacology. *Drug Saf.* 1998; 19:465–480. [PubMed: 9880090]
32. Al-Rashid ZF, Hsung RP. (+)-arisugacin A – computational evidence of a dual binding site covalent inhibitor of acetylcholinesterase. *Bioorg. Med. Chem. Lett.* 2011; 21:2687–2691. [PubMed: 21216144]
33. Polydoro M, Acker CM, Duff K, Castillo PE, Davies PJ. Age-dependent impairment of cognitive and synaptic function in the tau mouse model of tau pathology. *Neurosci.* 2009; 29:10741–10749.
34. Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. *J. Nat. Prod.* 2012; 75:311–335. [PubMed: 22316239] ■ This coverage of 30 years of natural products shows that natural products are an inestimable source of drug discovery.
35. Necula M, Chirita CN, Kuret J. Cyanine dye N744 inhibits tau fibrillization by blocking filament extension: implications for the treatment of tauopathic neurodegenerative diseases. *Biochemistry.* 2005; 44:10227–10237. [PubMed: 16042400]
36. de Calignon A, Fox LM, Pitstick R, et al. Caspase activation precedes and leads to tangles. *Nature.* 2010; 464:1201–1204. [PubMed: 20357768]
37. Eisenberg D, Nelson R, Sawaya MR, et al. The structural biology of protein aggregation diseases: fundamental questions and some answers. *Acc. Chem. Res.* 2006; 39:568–575. [PubMed: 16981672]
38. Hanger DP, Anderton BH, Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. *Trends Mol. Med.* 2009; 15:112–119. [PubMed: 19246243]
39. Mazanetz MP, Fischer PM. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. *Nat. Rev. Drug Discov.* 2007; 6:464–479. [PubMed: 17541419]



40. Gong CX, Iqbal K. Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. *Curr. Med. Chem.* 2008; 15:2321–2328. [PubMed: 18855662]
41. Medina M, Castro A. Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic. *Curr. Opin. Drug Discov. Dev.* 2008; 11:533–543.
42. Selenica ML, Jensen HS, Larsen AK, et al. Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the post natal rat model of tau hyperphosphorylation. *Br. J. Pharmacol.* 2007; 152:959–979. [PubMed: 17906685]
43. Ishihara T, Hong M, Zhang B, et al. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. *Neuron.* 1999; 24:751–762. [PubMed: 10595524]
44. Zhang B, Maiti A, Shively S, et al. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. *Proc. Natl Acad. Sci. USA.* 2005; 102:227–223. [PubMed: 15615853]
45. Williams P, Sorribas A, Howes MJR. Natural products as a source of Alzheimer's drug leads. *Nat. Prod. Rep.* 2011; 28:48–77. [PubMed: 21072430]
46. Da Rocha MD, Dias Viegas FP, Campos HC, et al. The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders II: Alzheimer's disease. *CNS Neurol. Disord. Drug Targets.* 2011; 10:251–270. [PubMed: 20874701]
47. Gu Y, Nieves JW, Stern Y, Luchsinger JA, Scarmeas N. Food combination and Alzheimer disease risk: a protective diet. *Arch. Neurol.* 2010; 67:699–706. [PubMed: 20385883]
48. Howes MJ, Houghton PJ. Ethnobotanical treatment strategies against Alzheimer's disease. *Curr. Alzheimer Res.* 2012; 9:67–85. [PubMed: 22329652]
49. Shytle RD, Bickford PC, Rezai-zadeh K, et al. Optimized turmeric extracts have potent anti-amyloidogenic effects. *Curr. Alzheimer Res.* 2009; 6:564–571. [PubMed: 19715544]
50. Shytle RD, Tan J, Bickford PC, et al. Optimized turmeric extract reduces  $\beta$ -amyloid and phosphorylated tau protein burden in Alzheimer's transgenic mice. *Curr. Alzheimer Res.* 2012; 9:500–506. [PubMed: 21875408]
51. Jones J, Lebar MD, Jinwal UK, et al. The diarylheptanoid (+)-aR,11S-myricanol and two flavones from bayberry (*Myricacerifera*) destabilize the microtubule-associated protein tau. *J. Nat. Prod.* 2011; 74:38–44. [PubMed: 21141876] ■■ (+)-aR,11S-myricanol represents a new scaffold for tau-targeting natural products and synthetic derivatives development.
52. Mounnissamy VM, Kavimani S, Gunasegaran R. Antibacterial activity of gossypetin isolated from hibiscus sabdariffa. *Antiseptic.* 2009; 99:81–82.
53. Shiota S, Shimizu M, Mizushima T. Marked reduction in the minimum inhibitory concentration (MIC) of beta-lactams in methicillin-resistant *Staphylococcus aureus* produced by epicatechingallate, an ingredient of green tea (*Camellia sinensis*). *Biol. Pharm. Bull.* 1999; 22:1388–1390. [PubMed: 10746177]
54. Taniguchi S, Suzuki N, Masuda M. Inhibition of heparin-induced tau filament formation by phenothiazines, polyphenols, and porphyrins. *J. Biol. Chem.* 2005; 280:7614–7623. [PubMed: 15611092]
55. Peterson DW, George RC, Scaramozzino F, Lapointe NE, Anderson RA, Graves DJ, et al. Cinnamon extract inhibits tau aggregation associated with Alzheimer's disease *in vitro*. *J. Alzheimers Dis.* 2009; 17:585–597. [PubMed: 19433898]
56. Pasinetti GM, Ksiezak-Reding H, Santa-Maria I, Wang J, Ho L. Development of a grape seed polyphenolic extract with antioligomeric activity as a novel treatment in progressive supranuclear palsy and other tauopathies. *J. Neurochem.* 2010; 114:1557–1568. [PubMed: 20569300]
57. Luvone T, De Filippis D, Esposito G, D'Amico A, Izzo AA. The spice sage and its active ingredient rosmarinic acid protect PC12 cells from amyloid- $\beta$  peptide-induced neurotoxicity. *J. Pharmacol. Exp. Ther.* 2006; 317:1143–1149. [PubMed: 16495207]
58. Shi LL, Yang WN, Chen XL, et al. The protective effects of tanshinone IIA on neurotoxicity induced by  $\beta$ -amyloid protein through calpain and the p35/Cdk5 pathway in primary cortical neurons. *Neurochem. Int.* 2012; 61(2):227–235. [PubMed: 22561406]

59. Ohtsuki K, Miyai S, Yamaguchi A, Morikawa K, Okano T. Biochemical characterization of novel lignans isolated from the wood of *Taxus yunnanensis* as effective stimulators for glycogen synthase kinase-3 $\beta$  and the phosphorylation of basic brain proteins by the kinase *in vitro*. *Biol. Pharm. Bull.* 2012; 35:385–393. [PubMed: 22382326]
60. Li W, Sperry JB, Crowe A, et al. Inhibition of tau fibrillation by oleocanthal via the reaction of the amino group of tau. *J. Neurochem.* 2009; 110:1339–1351. [PubMed: 19549281]
61. Pickhardt M, Gazova Z, von Bergen M, et al. Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments *in vitro* and in cells. *J. Biol. Chem.* 2005; 280:3628–3635. [PubMed: 15525637]
62. Radenahmad N, Saleh S, Sawangjaroen K, et al. Young coconut juice, a potential therapeutic agent that could significantly reduce some pathologies associated with Alzheimer's disease: novel findings. *Br. J. Nutr.* 2011; 105:738–746. [PubMed: 21114897]
63. Li L, Liu J, Yan X, et al. Protective effects of ginsenoside Rd against okadaic acid-induced neurotoxicity *in vivo* and *in vitro*. *J. Ethnopharmacol.* 2011; 138:135–141. [PubMed: 21945003]
64. Chaudan NB. Effect of aged garlic extract on APP processing and tau phosphorylation in Alzheimer's transgenic model Tg2576. *J. Ethnopharm.* 2006; 108:385–394.
65. Miethbauer S, Gaube F, Möllmann U, et al. Antimicrobial, antiproliferative, cytotoxic, and tau inhibitory activity of rubellins and caeruleoramularin produced by the phytopathogenic fungus *Colletotrichum cygni*. *Planta Med.* 2009; 75:1523–1525. [PubMed: 19565437]
66. Bedin M, Gaben AM, Saucier C, Mester J. Geldanamycin, an inhibitor of the chaperone activity of HSP90, induces MAPK-independent cell cycle arrest. *Int. J. Cancer.* 2004; 109:643–652. [PubMed: 14999769]
67. Forloni G, Colombo L, Girola, Tagliavini F, Salmona M. Anti-amyloidogenic activity of tetracyclines: studies *in vitro*. *FEBS Lett.* 2007; 487:404–407. [PubMed: 11163366]
68. Choi Y, Kim H, Shin KY, et al. Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models. *Neuropsychopharmacology.* 2007; 32:2393–2404. [PubMed: 17406652]
69. Familian A, Boshuizen RS, Eikelenboom P, Veerhuis R. Inhibitory effect of minocycline on amyloid beta fibril formation and human microglial activation. *Glia.* 2006; 53:233–240. [PubMed: 16220550]
70. Noble W, Garwood C, Stephenson J, Kinsey AM, Hanger DP, Anderton BH. Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease. *FASEB J.* 2009; 23:739–750. [PubMed: 19001528]
71. Zhang B, Carroll J, Trojanowski JQ, et al. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. *J. Neurosci.* 2012; 32:3601–3611. [PubMed: 22423084]
72. Cornejo A, Jimenez JM, Caballero L, Melo F, Maccioni RB. Fulvic acid inhibits of tau fibrils associated with Alzheimer's disease. *J. Alzheimer Dis.* 2011; 27:143–153.
73. Carrasco-Gallardo C, Guzman L, Maccioni RB. Shilajit: a natural phytocomplex with potential precognitive activity. *Int. J. Alzheimer Dis.* 2012:1–4.
74. Das V, Miller JH. Microtubule stabilization by peloruside A and paclitaxel rescues degenerating neurons from okadaic acid-induced tau phosphorylation. *Eur. J. Neurosci.* 2012; 35:1705–1717. [PubMed: 22594877]
75. Alfano G, Cimino G, De Stefano S. Palinurin, a new linear sesterterpene from a marine sponge. *Experientia.* 1979; 35:1136–1137.
76. Sakai R, Higa T, Jefford CW, Bernardinelli G. Manzamine A, a novel antitumor alkaloid from a sponge. *J. Am. Chem. Soc.* 1986; 108:6404–6405.
77. Cimino G, de Rosa S, de Stefano S, Mazzarella L, Puliti R, Sodano G. Isolation and x-ray crystal structure of a novel bromo-compound from two marine sponges. *Tetra. Lett.* 1982; 23:767–768.
78. Hamann M, Alonso A, Martin-Aparicio E, et al. Glycogen synthase kinase-3 (GSK-3) inhibitory activity and structure-activity relationship (SAR) studies of the manzamine alkaloids. Potential for Alzheimer's disease. *J. Nat. Prod.* 2007; 70:1397–1405. [PubMed: 17708655]

79. Meijer L, Thunnissen A, White AW, et al. Inhibition of cyclin-dependent kinases, GSK-3 $\beta$  and CK1 by hymenialdisine, a marine sponge constituent. *Chem. Biol.* 2000; 7:51–63. [PubMed: 10662688]
80. Meijer L, Skaltsounis AL, Magiatis P, et al. GSK-3-selective inhibitors derived from tyrianpurple indirubins. *Chem. Biol.* 2003; 10:1255–1266. [PubMed: 14700633] ■ The mollusk-derived bromoindirubins provide a promising scaffold for the development of selective and strong inhibitors of GSK-3 $\beta$ , which can be triggered to reduce phosphorylated tau.
81. Zhu M, Rajamani S, Kaylor J, Han S, Zhou F, Fink AL. The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils. *J. Biol. Chem.* 2004; 279:26846–26857. [PubMed: 15096521]
82. Kocisko DA, Baron GS, Rubenstein R, Chen J, Kuizon S, Caughey B. Drugs and natural products protein formation in a library of 2,000 new inhibitors of scrapie-associated prion. *J. Virol.* 2003; 77:10288–10294. [PubMed: 12970413]
83. Monti MC, Margarucci L, Tosco A, Riccio R, Casapullo A. New insights on the interaction mechanism between tau protein and oleocanthal, an extra-virgin olive-oil bioactive component. *Food Funct.* 2011; 2:423–428. [PubMed: 21894330]
84. Alam MI, Beg S, Samad A, et al. Strategy for effective brain drug delivery. *Eur. J. Pharm. Sci.* 2010; 40:385–403. [PubMed: 20497904] ■ Highlights the importance of drug delivery to make the CNS-related disease treatment effective.
85. Yang F, Lim GP, Begum AN. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid *in vivo*. *J. Biol. Chem.* 2005; 280:5892–5901. [PubMed: 15590663]
86. Janle EM, Lila MA, Wood L, et al. Kinetics and tissue distribution on 14C-labeled grape polyphenol fractions. *FASEB J.* 2007; 21:837.
87. Jager AK, Saaby L. Flavonoids and the CNS. *Molecules.* 2011; 16:1471–1485. [PubMed: 21311414]
88. Jin J, Lee WS, Joo KM, et al. Preparation of blood–brain barrier-permeable paclitaxelcarrier conjugate and its chemotherapeutic activity in the mouse glioblastoma model . *Med. Chem. Commun.* 2011; 2:270–273.

## Patents

101. Dickey, C.; Lebar, MD.; Baker, BJ.; Jones, J. WO2012012798. 2012.
102. Gordillo, DA.; Diaz, ID.; Gil, AM., et al. WO054221. 2004.

## Website

201. ClinicalTrials.gov. <http://clinicaltrials.gov>

### Executive summary

#### Understanding Alzheimer's disease progression is crucial to finding a cure for a rising aging population


- Current commercially available drugs for Alzheimer's disease (AD) are AChE inhibitors. Tacrine, donepezil, and the natural product-derived galantamine and rivastigmine can alleviate symptoms of AD and may have modifying effect on the disease.
- Mechanisms of AD development and progression are not well known. However, two major theories are the amyloid and tau hypotheses.

#### A switch in drug-discovery strategy from the A $\beta$ to the tau hypothesis


- Due to the limited success of A $\beta$ -based drugs in clinical trials, tau-based therapeutics have emerged as a potential alternative.
- Two drugs based on the tau hypothesis are already in Phase II clinical trials. The outcomes of these trials will provide more information about the viability of the tau strategy.

#### Natural products are a rich source of diverse scaffolds for AD drug discovery


- Many drugs are derived from natural products including two of the four available AD drugs based on AChE.
- Based on current successes, natural products may provide new resources for the discovery of novel and more effective drugs for AD.




**Figure 1.**  
Breaking down of acetylcholine by acetylcholine esterase.



**Figure 2. The tau hypothesis of Alzheimer's disease progression**  
NFT: Neurofibrillary tangles; PHF: Paired helical filaments.




**Figure 3.**  
AChE inhibitors galantamine (1), rivastigmine (2) and physostigmine (3).




**Figure 4.**  
Plant-derived tau-targeting natural products.







**Figure 5.**  
Plant-derived tau-targeting natural products.




**Figure 6. Paclitaxel**  
Plant-derived microtubule stabilizer drug as tau-targeting natural product.



**Figure 7.**  
Microbe-derived tau-targeting natural products.



**Figure 8.**  
Microbe-derived tau-targeting natural products (34 & 35).



**Figure 9.** Marine macro-organism-derived tau-targeting natural products.

Table I

Alzheimer's disease drugs and selected compounds in various stages of clinical trials.

Compound	Trade name	Source	Pathway	Status	Year of approval (US FDA)
Tacrine	Cognex®	Synthetic	AChE inhibitors	Market	1993
Donepezil	Aricept®	Synthetic	AChE inhibitors	Market	1996
Rivastigmine	Exelon®	Synthetic (natural product-inspired)	AChE inhibitors	Market	2000
Galantamine	Razadyne®	Natural product (plant)	AChE inhibitors	Market	2001
Memantine	Axura®, Namenda®, Abixa® and Memox	Synthetic	N-methyl-D-aspartate receptor antagonist	Market	2004
Curcumin		Natural product (plant)	A $\beta$ plaques	Phase II	
Homotaurine	Alzhamed™	Natural product (algae)	A $\beta$ plaques	Phase III (failed)	
R-flurbiprofen	Flurizan™	Synthetic	A $\beta$ plaques	Phase III (failed)	
Minocycline		Synthetic (natural product-inspired)	A $\beta$ /tau/microglia	Phase II	
Methylene blue	Rember™	Synthetic	Tau aggregation	Phase II	
Tideglusib	Zentylor™	Synthetic	Tau aggregation	Phase II	

Data taken from [27,201].